Dupixent
E561777
Dupixent is a prescription biologic medication (dupilumab) used to treat moderate-to-severe inflammatory conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Dupixent canonical | 2 |
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biologic medication
ⓘ
monoclonal antibody ⓘ prescription drug ⓘ |
| hasActiveIngredient | dupilumab ⓘ |
| hasATCCode | L04AC13 ⓘ |
| hasBrandOwner |
Regeneron Pharmaceuticals
NERFINISHED
ⓘ
Sanofi NERFINISHED ⓘ |
| hasCommonSideEffect |
blepharitis
ⓘ
conjunctivitis ⓘ eosinophilia ⓘ injection site reactions ⓘ oral herpes ⓘ |
| hasDosageForm |
pre-filled pen
ⓘ
pre-filled syringe ⓘ |
| hasDrugClass |
immunomodulator
ⓘ
interleukin inhibitor ⓘ |
| hasFDAApprovalStatus | approved ⓘ |
| hasGenericName | dupilumab NERFINISHED ⓘ |
| hasPregnancyCategory | insufficient human data ⓘ |
| hasRouteOfAdministration | subcutaneous injection ⓘ |
| hasTarget | type 2 inflammation pathway ⓘ |
| inhibitsPathway |
IL-13 signaling
ⓘ
IL-4 signaling ⓘ |
| isAdministeredBy | subcutaneous injection ⓘ |
| isAdministeredOn | every-other-week schedule ⓘ |
| isCoDevelopedBy | Sanofi NERFINISHED ⓘ |
| isContraindicatedIn | patients with known hypersensitivity to dupilumab ⓘ |
| isDevelopedBy | Regeneron Pharmaceuticals NERFINISHED ⓘ |
| isIndicatedFor |
adults with chronic rhinosinusitis with nasal polyps
ⓘ
adults with eosinophilic esophagitis ⓘ adults with moderate-to-severe asthma ⓘ adults with moderate-to-severe atopic dermatitis ⓘ adults with prurigo nodularis ⓘ pediatric patients with moderate-to-severe asthma ⓘ pediatric patients with moderate-to-severe atopic dermatitis ⓘ |
| isNot |
a corticosteroid
ⓘ
a systemic immunosuppressant ⓘ |
| targetsMolecule | interleukin-4 receptor alpha NERFINISHED ⓘ |
| treatsCondition |
asthma
ⓘ
atopic dermatitis ⓘ chronic rhinosinusitis with nasal polyps ⓘ chronic spontaneous urticaria ⓘ eosinophilic asthma ⓘ eosinophilic esophagitis ⓘ moderate-to-severe asthma ⓘ moderate-to-severe atopic dermatitis ⓘ oral corticosteroid-dependent asthma ⓘ prurigo nodularis ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.